Article information
RESUMO
A hipertensão pulmonar primária (HPP) é uma doença grave que atinge preferencialmente mulheres jovens. A compreensão da sua f'isiopatologia tem permitido a introdução de importantes avanços terapêuticos, nomeadamente a anticoagulação, os vasodilatadores orals e a prostaciclina intravenosa contínua, nos doentes que não respondem a urn teste agudo de vasodilatação durante o cateterismo dircilo. Umu via de administração atractiva para os prostanóidcs parece ser a via inalatória recorrendo a arálogos estáveis da prostaciclina, como o iloprost. Outros fármacos e outras vias de adminiotralção encontram-se também em investigação. A transplantação pulmonar ou coração-pulmão permanece como urn último recurso e a septostomia auricular como uma altemativa valida. Os autores revêem a fasiopatologia, a metodologia de diagnóstico, a terapêutica e o prognóstico da HPP.
REV PORT PNEUMOL 2000; VI (5): 383-394
Palavras-chave:
Hipertensão pulmonar primána
Bloqueantes do cálcio
Epoprostcnol
Prostanóides
lloprost
ABSTRACT
Primary pulmonary hypertension (PPH) is a serious disease affecting mainly young women. The understanding of its physiopathology bas led to the development or therapeutic advances, namely anticoagulation, oral vasodilators and continuous intravenous prostacyclio for those patients that do not react to an acute vasodilation test during right heart cathetberization. An attractive administration route see.ris to be the Jnbalative one, using more stable prostacyclin analogues like iloprost. Other drugs and administration routes are currently beeing investigated. Lung or heart-lung transplantation remains as a last resource and baJion blade atrial septostomy as a valid alternative. The authors review the physiopathology, diagnostic methodology, therapeutic option and prognosis of PPH.
REV PORT PNEUMOL 2000; VI (5): 383-394
Key-words:
Primary pulmonary hypertension
Calcium channel blockers
Epopros tenol
Prostanoids
lloprost
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
L. Rubin.
ACCP consensus statement: primary pulmonary hypertension.
Chest, 104 (1987), pp. 236-250
[2.]
S.P. Gaine, L.J. Rubin.
Primary pulmonary hypertension.
The Lancet, 352 (1998), pp. 719-725
[3.]
A. Costa, et al.
Hipcrtensão pulmonar primãna -apresentação de um caso clínico e revisão da literatura.
Arq Med, 10 (1996), pp. 200-203
[4.]
M.J.M. Gomes, et al.
A insuficiência cardíaca no doente pulmonar crónico.
Gerialria, 10 (1997), pp. 26-34
[5.]
J.M. Santos, et al.
Des-saruração noctuma e hipertensão da artéria pulmonar em doentes com bronquite crónicaenfisema e PaO2 55-70mmHg.
Rev Port Pneumol J, 2 (1996), pp. 65-73
[6.]
E. Romberg.
Ueber Sklerose der Lungen arterie.
Dtsch Archiv Klin Med, 48 (1891), pp. 197-206
[7.]
S. Rich.
Primary Pulmonary Hypertension.
Executive Summary. World Symposium – Primary Pulmonary Hypertension 1998 Evian,
[8.]
L. Abenhaim, et al.
Appetite-supressant drugs and the risk of primary pulmonary hypertension.
N Engl J Med, 335 (1996), pp. 609-616
[9.]
A.F. Vaz.
Doença valvular cardíaca e anorexígenos.
Bol Farmacovigil, 1 (1997), pp. 2
[10.]
J. Loy, et al.
Familial primary pulmonary hypertension: clinical patterns.
Am Rev Resp Dis, 129 (1984), pp. 194-197
[11.]
C. Nascjmento, et al.
Hipertensão pulmonar primária familiar.
Med lntema, 6 (1999), pp. 111-113
[12.]
M.A.T. Marques, et al.
Hipertensãio arterial pulmonar primitiva familiar.
Arq Soc Port Patol Respir, 11 (1994), pp. 17-26
[13.]
S. Rich, et al.
Primary pulmonary nypenension: a national prospective study.
Ann lntem Med, 107 (1987), pp. 216-223
[14.]
L.J. Rubin.
Primary pulmonary hypertension.
N Eng J Med, 336 (1997), pp. 111-117
[15.]
F. Maltez, et al.
Hipertensão pulmonar primária e vírus da imunodeficiência humana - a propósito de urn caso clínico.
Rev Port Doenc lnfec, 21 (1998), pp. 193-196
[16.]
G. Nogueira, et al.
Morbilidade cardiovascular em crianças com infecção pclo vírus da lmunodcficiência humana.
Acta Med Port, 11 (1998), pp. 1051-1057
[17.]
W. Nichols, et al.
Localization of the gene for familial primary hypertension to chromosome 2q31-32.
Nat Genet, 42 (1997), pp. 1163-1184
[18.]
X.-J. Yuan, et al.
Attenuated K+ channel gene transcription in primary pulmonary hypertension.
Lancet, 352 (1998), pp. 726-727
[19.]
N. Voelkl, et al.
Pathophysiology of primary pulmonary hypertensiom: from physiology to molecular mechanisms.
Primary pulmonary hypertension, pp. 3-130
[20.]
P. Azevedo, et al.
Diagnóstico não invasivo de hipertensão pulmonar e cor pulmonale nos doentes com a doenya pulmonar crónica obstrutiva - importância da ecocardiografia.
Rev Port Pneumol, 1 (1995), pp. 59-65
[21.]
R. Kessler, et al.
Pulmonary hypertension in lhe obstruc tive sleep apnea syndrome: prevalence, causes and thera peutic consequences.
Eur Respir J, 9 (1996), pp. 787-794
[22.]
R.J. Barst, et al.
A comparision of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary hypertension: the Primary Pulmonary Hypertcnsi on Study group.
N Eng J Med, 334 (1996), pp. 296-302
[23.]
S. Miyamoto, et al.
Clinical Correlates and Prognostic Significance of Six-minute walk test in Patients with Primary Pulmonary Hypertension. Comparison wilh cardiopulmonary exercise testing.
Am J Respir Crit Care Med, 161 (2000 Feb 1), pp. 487-492
[24.]
D. Georgiou, et al.
Hemodynamic Evaluation in Primary Pulmonary Hypertension.
Primary pulmonary hypertension, pp. 83-130
[25.]
S. Rich, et al.
The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension.
N Engl J Med, 327 (1992), pp. 76-81
[26.]
O. Sitbron, et al.
Inhaled Nitric Oxide as a screening Vasodilator Agent in Primary Pulmonary Hypertension. A dose response study and a comparison with prostacyclin.
Am J Respir Crit Care Med, 151 (1995), pp. 384-389
[27.]
O. Raffy, et al.
Clinical significance of the Pulmonary Vasodilator Response During Short-term lnfusion of Prostacyclin in Primary Pulmonary Hypertension.
Circula- lion, 93 (1996), pp. 484-488
[28.]
S. Rich, et al.
ACCP consensus statement: Primary Pulmonary Hypertension.
Chest, 104 (1993), pp. 236-250
[29.]
S. Fuster, et al.
Primary pulmonary hypertension: natural history and the importance of thrombosis.
Circulation, 70 (1984), pp. 580-587
[30.]
S. Rich, et al.
The effect of high doses of calciwn channel blockers on surtival in primary pulmonary hypertension.
N Eng J Med, 327 (1992), pp. 76-81
[31.]
U. Rubin, et al.
Medical Management.
Primary pulmonary hypertension, pp. 271-286
[32.]
R.J. Rubin, et al.
Survival in primary pulmonary hyperten sion with long-term intravenous prostacyclin (epoprostenol).
Ann Intern Med, 1 (1990), pp. 485-495
[33.]
R.J. Barst, et al.
Survival in primary pulmonary hypcrten sion with long term intravenous prostacyclin.
Ann Intern Med, 121 (1994), pp. 409-415
[34.]
R.J. Barst, et al.
A comparison of continuous intravenous prostacyclin versus conventional therapy in primary pulmonary hypertension.
N Eng J Med, 334 (1996), pp. 296-301
[35.]
J.P. Scott, et al.
The acute effect of lhe synthetic prostacyclin analogue iloprost in primary pulmonary hypertension.
Brit J Clin Pract, 44 (1990), pp. 231-234
[36.]
T.W. Higenbottam, et al.
Treatment of pulmonary hypertension with the continuous infusion of a prostacy clin analogue, iloprosl.
Heart, 79 (1998), pp. 175-179
[37.]
M.M. Ahoeper, et al.
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension.
J Am Coll Cardiol, 35 (2000), pp. 176-182
[38.]
H. Olschewsky, et al.
Aerosolized prostaeyclin and iloprost in severe pulmonary hypertension.
Ann lntem Med, 124 (1996), pp. 820-824
[39.]
H. Olschewsky, et al.
Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost.
lmensive Care Med, 24 (1998), pp. 631-634
[40.]
K. Parameswaran, et al.
Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.
Rcspir. Med., 93 (1999), pp. 75-78
[41.]
D. Walmrath, et al.
Aerosolised prostacyclin in adult respiratory distress syndrome.
Lancet, 342 (1993), pp. 961-962
[42.]
Van Heerden, et al.
Inhaled aerosolized prostacyclin and nitric oxide as a selective pulmonary vasodilators in ARDS - A pilot study.
Anaesth Intens Care, 24 (1996), pp. 564-568
[43.]
H. Olschewsky, et al.
1nhalcd prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Am J Respir Crit Care Med, 160 (1999), pp. 600-607
[44.]
M.M. Hoeper, et al.
Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary vena-occlusive disease.
Respiratory Mçdicine, 93 (1999), pp. 62-70
[45.]
J.D. Hosenpud, et al.
The registry of the International Society for Heart and Lung Transplantation: fourteenth official rcport.-1997.
J Heart Lung Transplant, 16 (1997), pp. 691-712
[46.]
B.A. Reitz, et al.
Heart-lung transplantation. Successful therapy for patients with pulmonary vascular disease.
N Eng J Med, 306 (1982), pp. 557-564
[47.]
Group Tlt.
Unilateral lung transplantation for pulmo nary fibrosis.
N Eng J Med, 314 (1986), pp. 1140-1145
[48.]
M.K. Pasque, et al.
Improved technique for bi1aterallung transplantation: rationale and initial clinical experience.
Ann Thorac Surg, 49 (1990), pp. 785-791
[49.]
B.F. Meyers, et al.
Lung transplantation – current issues and evolving concepts. Sem Resp.
Crit Care Med, 20 (1999), pp. 429-438
[50.]
New and Emerging Treatments for Pulmonary Hypertension.
American Thoracic Society Postgraduate Course, (April 1999),
[51.]
O. Kerstein, et al.
Blade balloon atrial septostomy improves survival in patients with primary pulmonary hypertension.
Circulation, 91 (1995), pp. 2008-2035
[52.]
M.D. McGoon.
Prognosis and Natural History.
Primary pulmonary hypertension, pp. 305-317
Copyright © 2000. Sociedade Portuguesa de Pneumologia/SPP
Special content about COVID-19
- Assisted mobilisation in critical patients with COVID-19
- Two years of COVID-19: Trends in rehabilitation
- Comparison of different field tests to assess the physical capacity of post-COVID-19 patients
- New insights in circulating peptidome to differentiate mild to severe COVID-19 patients: Preliminary report
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options